ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

Other illness

• Suggest patients with active hepatitis B or C virus infection
• History of immunodeficiency, including a positive human immunodeficiency virus (HIV) antibody test.
• Subjects have another active malignancy within the past 2 years before study entry, except for curatively treated.

Other

• R/R AML or R/R MDS with no response or intolerance to post azacitidine or BCL-2i.
• Subject has acute promyelocytic leukemia (French-American-British Class M3 AML) .
• Subject has known central nervous system (CNS) leukemia.

• Eligible subjects must meet all of the following criteria:
• Subject must have confirmation of diagnosis of AML (except for acute promyelocytic leukemia \[APL\]) or MDS per 2016 World Health Organization (WHO) criteria.
• For AML (except for APL) cohort:
  • Previously treated relapsed/refractory AML subjects
  • Treatment-naïve AML subjects should be: ≥60 years of age OR ≥18 years and \<60 years will be eligible if the subject has at least one of the following co-morbidities, which make the subject unfit for intensive chemotherapy
• For MDS cohort: Adult TN MDS and R/R MDS: revised International Prognostic Scoring System (IPSS-R) score \> 3 and bone marrow blasts ≥ 5%.
• Subject must have a projected life expectancy of at least 12 weeks.
• Subject must have adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft-Gault formula.
• Subject must have adequate liver function